Efficacy and tolerability of a botulinum toxin type a free of complexing proteins (NT 201) compared with commercially available botulinum toxin type a (BOTOX®) in healthy volunteers

Journal of Neural Transmission

Volumn 112, Issue 7, 2005, Pages 905-913

  Jost, W H ^a   Kohl, A ^a   Brinkmann, S ^b   Comes, G ^b  

^a DEUTSCHE KLINIK FÜR DIAGNOSTIK   (Germany)

^b MERZ PHARMACEUTICALS GMBH   (Germany)

Author keywords

Botulinum toxin type A; EDB test; NT 201

Indexed keywords

BOTULINUM TOXIN; BOTULINUM TOXIN A; NT 201; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; FOOT; HUMAN; HUMAN EXPERIMENT; MALE; MUSCLE; MUSCLE ACTION POTENTIAL; NORMAL HUMAN; PARALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS;

ACTION POTENTIALS; ADULT; BACTERIAL PROTEINS; BOTULINUM TOXIN TYPE A; HUMANS; MALE; MIDDLE AGED; MUSCLE, SKELETAL; NEUROMUSCULAR AGENTS; TIME FACTORS;

EID: 20944432519     PISSN: 03009564     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00702-004-0234-8     Document Type: Article

References (19)

1. Aoki KR (2001) A comparison of the safety margins of botulinum neurotoxin serotypes A B and F in mice. Toxicon 39: 1815-1820
2. Benecke R (2004) Efficacy and safety of a new botulinum toxin type A free of complexing proteins in treatment of cervical dystonia. Mov Disord 19 [Suppl 9]: S110-S111
3. Binz T, Kurazono H, Wille M, Frevert J, Wernars K, Niemann H (1990) The complete sequence of botulinum neurotoxin type A and comparison with other clostridial neurotoxins. J Biol Chem 265: 9153-9158
4. Chen F, Kuziemko GM, Amersdorfer P, Wong C, Marks JD, Stevens RC (1997) Antibody mapping to domains of botulinum neurotoxin serotype A in the complexed and uncomplexed forms. Infect Immun 65: 1626-1630
5. Dressler D, Dirnberger G (2001) Botulinum toxin antibody testing: comparison between the immunoprecipitation assay and the mouse diaphragm assay. Eur Neurol 45: 257-260
6. Eleopra R, Tugnoli V, Rossetto O, De Grandis D, Montecucco C (1998) Different time courses of recovery after poisoning with botulinum neurotoxin serotypes A and E in humans. Neurosci Lett 256: 135-138
7. Erbguth FJ, Naumann M (1999) Historical aspects of botulinum toxin Justinus Kerner (1786-1862) and the 'sausage poison'. Neurology 53: 1850-1853
8. Gordon PH, Gooch CL, Greene PE (2002) Extensor digitorum brevis test and resistance to botulinum toxin type A. Muscle Nerve 26: 828-831
9. Greene P, Shale H, Fahn S (1988a) Analysis of open-label trials in torsion dystonia using high dosages of anticholinergics and other drugs. Mov Disord 3: 46-60
10. Greene P, Shale H, Fahn S (1988b) Experience with high dosages of anticholinergic and other drugs in the treatment of torsion dystonia. In: Fahn S, Marsden CD, Calne DB (eds) Dystonia 2. Raven Press, New York, pp 547-556 (Adv Neurol 50)
11. Hamjian JA, Walker FO (1994) Serial neurophysiological studies of intramuscular botulinum-A toxin in humans. Muscle Nerve 17: 1385-1392
12. Jankovic J, Vuong KD, Ahsan J (2003) Comparison of efficacy and immunogenicity of original versus current botulinum toxin in cervical dystonia. Neurology 60: 1186-1188
13. Kessler KR, Benecke R (1997) The EBD test - a clinical test for the detection of antibodies to botulinum toxin type A. Mov Disord 12: 95-99
14. Roggenkämper P (2004) Efficacy and safety of a new botulinum toxin type A free of complexing proteins in treamtent of blepharospasm. Mov Disord 19 [Suppl 9]: S84-S85
15. Scott AB (1981) Botulinum toxin injection of eye muscles to correct strabismus. Trans Am Ophthalmol Soc 79: 734-770
16. Sloop RR, Cole BA, Escutin RO (1997) Human response to botulinum toxin injection: type B compared with type A. Neurology 49: 189-194
17. Sloop RR, Cole D, Patel MC (2001) Muscle paralysis produced by botulinum toxin type A injection in treated torticollis patients compared with toxin naive individuals. Mov Disord 16: 100-105
18. Sloop RR, Escutin RO, Matus JA, Cole BA, Peterson GW (1996) Dose-response curve of human extensor digitorum brevis muscle function to intramuscularly injected botulinum toxin type A. Neurology 46: 1382-1386
19. Wohlfarth K, Kampe K, Bigalke H (2004) Pharmacokinetic properties of different formulations of botulinum neurotoxin type A. Mov Disord 19: S65-S67